EW Edwards Lifesciences (EW) Q2 FY25 earnings call
Edwards Lifesciences delivered strong Q2 FY25 results, exceeding expectations with double-digit sales growth across its structural heart portfolio, notably TAVR and TMTT. The company raised its full-year sales and adjusted EPS guidance, driven by broad-based adoption of differentiated therapies and anticipated catalysts like asymptomatic AS approval and SAPIEN M3. Management remains confident in its long-term growth strategy and operating leverage goals, despite expected second-half margin pressures.
You’re reading a preview. Opening the full call uses 1 concall credit.
Sign in to use your monthly call allowance.
EW operating KPIs by quarter
| KPI | Dec 2024 Q4 FY24 | Mar 2025 Q1 FY25 | This call Jun 2025 Q2 FY25 | Dec 2025 Q4 FY25 | Mar 2026 Q1 FY26 | Jun 2026 Q2 FY26 | Change vs prior quarter |
|---|---|---|---|---|---|---|---|
| Employees | 16KIt was a year of strong growth and meaningful progress for Edwards as our 16,000 employees advanced life-saving structural heart technologies for patients around the world.Source: earnings call transcript | 16KI'd like to thank our 16,000 global employees for their many contributions to advancing patient care.Source: earnings call transcript | 16KWe are confident that our unique innovation strategy supported by the many important catalysts across our portfolio and the exceptional work of our 16,000 employees around the world will deliver significant value to patients the health care ecosystem and shareholders.Source: earnings call transcript | 16KOur talented team of 16,000 employees create, develop and enable treatment of patients globally.Source: earnings call transcript | 16KWe've built a workplace where our 16,000 employees around the world can stay and grow with us.Source: earnings call transcript | 16KOur 16,000 employees around the world are aligned with our vision, inspired by their work and dedicated to delivering exceptional innovation for patients in need.Source: earnings call transcript | 0% |
Operating figures the company stated on at least two of the calls shown, checked against each call's transcript. Click a figure to read the sentence. A dash means it was not stated that quarter.
Inve summary of the company's earnings call; see how call summaries are prepared. Not investment advice.